SCHEDULE 13G/A: AstraZeneca Updates Passive Stake in Conduit Pharmaceuticals to 1.1%
Beneficial Ownership Report
AstraZeneca PLC and its subsidiary AstraZeneca AB have filed an amended Schedule 13G, reporting a 1.1% passive beneficial ownership stake in Conduit Pharmaceuticals Inc.
Summary
- AstraZeneca PLC and its wholly-owned subsidiary, AstraZeneca AB, are the reporting persons in this Schedule 13G Amendment No. 1 filing.
- They collectively beneficially own 73,892 shares of Conduit Pharmaceuticals Inc.'s common stock.
- This ownership represents 1.1% of Conduit Pharmaceuticals Inc.'s total outstanding common stock.
- The percentage ownership is calculated based on 6,662,755 shares of Conduit Pharmaceuticals Inc. common stock outstanding as of March 28, 2025, as reported in the issuer's Form 10-K.
- Both AstraZeneca PLC and AstraZeneca AB are deemed to have sole voting and sole dispositive power over these 73,892 shares.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the issuer or the reporting entity.
Future Outlook
The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the future outlook of Conduit Pharmaceuticals Inc. or AstraZeneca.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Adrian Kemp, Company Secretary for AstraZeneca PLC, and Lars-Johan Cederbrant, Director and CFO for AstraZeneca AB)
Industry Context
This filing indicates a passive investment by AstraZeneca, a major global pharmaceutical company, in Conduit Pharmaceuticals Inc., which operates in a related sector. Such a small, passive stake typically reflects a portfolio investment rather than a strategic move implying control or significant collaboration within the industry.
Key Dates
| Date | Description |
|---|---|
| 03/28/2025 | Date as of which Conduit Pharmaceuticals Inc.'s common stock outstanding (6,662,755 shares) was reported in its Form 10-K. |
| 03/31/2025 | Date of event which required the filing of this statement. |
| 04/10/2025 | Date of filing of the Schedule 13G Amendment No. 1 by AstraZeneca PLC and AstraZeneca AB. |
Keywords
Conduit Pharmaceuticals Inc., AstraZeneca PLC, AstraZeneca AB, Schedule 13G, beneficial ownership, common stock, pharmaceuticals, biotechnology, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.